Clinical Trials on Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Total 5366 results

Michael Choi
Pharmacyclics LLC.

Active, not recruiting

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

Elderly Patients | Small Lymphocytic Lymphoma | CLL | B-cell | Untreated B-CLL

Italy
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Anemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
James Blachly
Novartis

Withdrawn

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome
Seema Bhat

Recruiting

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SecuraBio

Terminated

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Lymphoma, Small Lymphocytic | Lymphocytic Leukemia, Chronic

United States, Canada
Gilead Sciences

Completed

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic | Leukemia, Prolymphocytic | NHL | CLL | Leukemia, Lymphocytic, Chronic | Lymphoma, Intermediate-Grade | Lymphoma, Large-Cell | Lymphoma, Mixed-Cell | Lymphoma, Small-Cell | Leukemia, B-Cell, Chronic | Leukemia... and other conditions

United States
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia
Aptevo Therapeutics

Completed

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Non-Hodgkin's Lymphoma (NHL)

United States
Dana-Farber Cancer Institute
BeiGene

Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
Bristol-Myers Squibb

Withdrawn

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma (MDX1411-02)

Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
National Cancer Institute (NCI)

Terminated

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

United States
TG Therapeutics, Inc.

Terminated

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Small Lymphocytic Lymphoma | B-cell Lymphomas

United States
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
GlaxoSmithKline

Completed

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Japan
GlaxoSmithKline
Genmab

Completed

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

Leukaemia, Lymphocytic, Chronic

Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (ULTRA-V)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
AstraZeneca

Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma

India
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
Sumitomo Pharma America, Inc.

Terminated

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | SLL

United States
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Italy, Spain, France, Austria, United States
BeiGene

Recruiting

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia

United States
Jonsson Comprehensive Cancer Center
Gilead Sciences

Terminated

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma | Absence of Signs or Symptoms | Digestive System Signs and Symptoms | Indolent Adult Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Ruijin Hospital

Not yet recruiting

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Richter Syndrome | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Leudosite

Terminated

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Lymphoma, B-Cell | Lymphoma, T-Cell | Lymphoma, Low-Grade | Leukemia, Lymphocytic, Acute | Leukemia, Lymphocytic, Chronic

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
GlaxoSmithKline

Completed

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Leukaemia, Lymphocytic, Chronic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia (LLC1114)

Adult Patients | Chronic Lymphocyte Leukemia

Italy
Gilead Sciences

Terminated

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-hodgkin's Lymphoma | Small Lymphocytic Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
EUSA Pharma, Inc.

Recruiting

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Large Granular Lymphocyte Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia) | Monoclonal B-Cell Lymphocytosis

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Italy, Poland, Spain, Czechia, Canada, France
Dana-Farber Cancer Institute
GlaxoSmithKline; Gilead Sciences

Active, not recruiting

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Inhye Ahn
Loxo Oncology, Inc.

Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States

Clinical Trials on Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations